Tencent, Guoxin co-lead $97m Series E round in Chinese biopharma Evopoint

Tencent, Guoxin co-lead $97m Series E round in Chinese biopharma Evopoint

21 February, 2024

Edited by: Joymitra Rai

biopharmaceutical CICC Capital Evopoint Biosciences GIC Guoxin Investment Loyal Valley Capital STAR Market Tencent

Printed by Unregistered user on Fri, 29 Aug 2025 05:28:10 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Policy & Regulations

Chinese biotech firm WuXi AppTec denies it is a US national security threat

Biotech firm I-Mab to divest China operations amid US shift

Read more from Greater China

Logistics firm GLP secures up to $1.5b from ADIA unit

Earnings and Results

Data Vantage: Foundation Healthcare clocks profit; other financial updates